GlobeNewswire by notified

Pixium Vision announces its financial results for H1 2022 and provides a business update


Pixium Vision announces its financial results for H1 2022 and provides abusiness update

  • Cash position at 30 June 2022: €7,2 million
  • PRIMAvera European pivotal study ongoing and on track to report data around end 2023
  • Post period event: Implementation of a convertible note financing agreement with a maximum nominal amount of €30 million with ESGO, potentially extending cash runway until the middle of 2024, assuming all tranches are drawn1
  • Drawdown of the first tranche with a nominal value of €5,5 million on July 14, 2022, extending the cash runway to the first quarter of 2023

Paris, 22July2022 – 7.00 a.m. CET - Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for the first half of 2022. The H1 2022 financial statements were approved by Pixium Vision’s Board of Directors at its meeting on 20 July 2022.

Lloyd Diamond, CEO of Pixium Vision, commentedThe company is continuing its preparations in transforming Pixium Vision from a research to a commercial organization, with a number of significant milestones achieved in the first half of 2022. Clinically, we are making good progress with the PRIMAvera pivotal trial of our Prima System for bionic vision and have closed additional financing in order to ensure the success of our clinical programs.

The financial resultsare based on an improved financial position, with €7,2 million in cash at end of June 2022plus anadditional4,6 million2 through the new agreement signed with ESGO on July 13, 2022 giving access to a maximum of nominal €30 million financing, with improved terms compared to the previous agreement. In spite of the downturn of the financial markets, we are continuing to build successful interactions with investors globally to continue to ensure financing Pixium in the best possible wayadded Offer Nonhoff, CFO of Pixium Vision

H1 2022results - Excerpts

Income statement summary
In thousands of eurosH1 2022H1 2021 *Change
Operating revenue1,043.81,801.0(42.0) %
Current operating expenses(7,148.5)(6,631.3)+7.8%
Research and Development(4,086.1)(3,686.9)+10.8 %
General and administrative expenses(3,062.4)(2,944.4)+4.0 %
Operating loss(6,104.7)(4,830.4)+26.4%
Net loss for the period(5,614.3)(5,545.7)+1.2%
Net earnings per share(0.12)(0.12)

*H1 2021 restated: impact of change in IAS19 calculation (cf. note 3 IFRIC May 2021 – IAS19 Retirement Benefits of half year financial report 2022)

Statement of cash flows summary
In thousands of eurosH1 2022H1 2021
Opening cash and cash equivalents10,131.410,566.0
(Decrease)/Increase in cash position(7,283.6)(434.5)
O/W net cash flows from operating activities(7,064.1)(6,115.4)
O/W net cash flows from investment activities(26.8)(32.0)
O/W net cash flows from financing activities(196.4)5,712.9
Closing cash and cash equivalents7,221.210,131.4

Update on Pixium Vision’s business

Pixium Vision continued to make significant clinical and business progress in H1 2022, including continuing implanting patients in the European PRIMAvera pivotal trial evaluating the safety and efficacy of the Prima System in patients affected by dry Age-related Macular Degeneration (AMD), targeting the last implantation end of 2022.

The feasibility study in the US continued to make good progress and recently broadened its clinical centers to include Stanford Medicine. Implantations of all US patients in this study are expected to complete by the end of 2022.

In January 2022, peer reviewed data was published in Nature Communications demonstrating the clinical benefit of the PRIMA System in Dry AMD patients.

Despite the downturn on the financial markets, Pixium Vision was able to secure the financing as announced July 14, 2022. The Company is continuing to build on traction gained with global investors to secure its financing pipeline into the future.

Analysis of H1 2022 results

Operating revenue amounted to €1.0 million and is comprised of a Research Tax Credit (CIR) in the amount of €1.0 million.

Current Research and Development (R&D) expenses totalled €4.1 million, compared to €3.7 million the previous year. During the first half of 2022, Pixium Vision continued to strengthen its clinical team and opened several centers in Europe as part of its PRIMAvera study. In addition, the Group continued to develop and manufacture its Prima bionic vision system to ensure the progress of its ongoing clinical studies.

Current general and administrative (G&A) expenses totalled €3.1 million in H1 2022, compared to €2.9 million in H1 2021. General and administrative expenses increased by 4.0% in H1 2022, mainly due to the costs the Group incurred for legal services in preparation of various financing options such as convertible bonds, private placement with French or international investors on Euronext Growth or on a foreign stock exchange.

In H1 2022, the Group did not recognize any marketing and sales expenses.

Operating result presented a loss of €6.1 million, which is higher than in H1 2021 (€4.8 million). Net result was a loss of €5.6 million (compared to a loss of €5.5 million in H1 2021). The loss per share is €0.12 for both periods.

Net cash outflow from operating activities increased in H1 2022 to €7.1 million, compared to €6.1 million in H1 2021. The increase in net cash outflow reflects the continuation of the PRIMAvera study, the US feasibility study, as well as the spending associated with the preparation of financing options.

Net cash flows from financing activities totalled €(0.2) million which are mainly related to the repayment of lease liabilities under IFRS16 in H1 2022. In H1 2021, financing activities reflected primarily the drawdown of 5 ORNAN tranches for a total of €6.25 million in gross proceeds under its agreement with ESGO.

Pixium Vision ended H1 2022 with a net cash position of €7.2 million, compared to €10.1 million a year earlier.

Post-period, on July 14, 2022, Pixium Vision announced the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche with a nominal value of €5.5 million.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- or on the Company’s website.

For more information:

Follow us on @PixiumVision;


Pixium Vision
Offer Nonhoff
Chief Financial Officer
+33 1 76 21 47 68
Media Relations

LifeSci Advisors
Sophie Baumont
+33 6 27 74 74 49
Investor Relations
LifeSci Advisors
Guillaume van Renterghem
+41 76 735 01 31

1 Subject to certain conditions as stipulated in the agreement signed with ESGO July 13, 2022
2 Includes a deduction of €500,000 from the first Tranche of the agreement signed July 13, 2022, which relates to the previous agreement that expired on May 13, 2022.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Graduate Management Admission Council Appoints Joy Jones as Incoming CEO8.8.2022 18:00:00 CEST | Press release

Jones to succeed Sangeet Chowfla as head of the global association representing leading graduate business schools RESTON, Va., Aug. 08, 2022 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today announced the appointment of Joy Jones as the organization’s CEO-Elect. Jones currently serves as GMAC’s chief product officer and general manager of assessments, a role she has held since July 2017. The announcement came after current CEO Sangeet Chowfla announced his intention to step down from the position earlier this year, and an extensive search executed by a global executive recruiting firm. The GMAC board of directors unanimously voted to elect Jones, who will become GMAC’s fourth CEO as of October 1, 2022. “With more than a hundred interested candidates from around the world, the Board conducted extensive interviews and thorough evaluations over the past months and was thrilled to find the best person to l

GeoJunxion (GOJXN.AS) announces the booking of a series of Location Intelligence Service contracts with combined value of well over one Million Euro8.8.2022 18:00:00 CEST | Press release

Capelle aan den IJssel, The Netherlands – 8 August 2022 – GeoJunxion (GOJXN.AS) is pleased to announce the booking of a series of Location Intelligence Service contracts with combined value of well over one Million Euro. The first 40 days of the new Financial Year 2022/23 (1 July 2022 - 30 June 2023) have been particularly busy and exciting for the various teams in GeoJunxion. As result of this, GeoJunxion is pleased to announce the booking of a series of Location Intelligence Services for one of its major global IT customers, with a combined value well over one Million Euro. In response to an increasing demand for hyper local content, GeoJunxion has closed a series of extensions to existing service contracts and successfully completed the negotiations on a large new tailor-made Location Intelligence Service contract. These new contracts will convert into revenue over the next 3 to 6 months and will contribute substantially to the continued growth of the company’s top- and bottom-line.

INVITATION TO CONFERENCE CALL FOR DFDS' REPORT FOR Q2 20228.8.2022 17:48:27 CEST | Press release

INVESTOR NEWS no. 22 - 8 August 2022 DFDS expects to publish the report for Q2 2022 on 16 August 2022 at around 07:30 CET. Torben Carlsen, CEO, and Karina Deacon, CFO, will present the report on a live conference call. The presentation in English will be followed by a Q&A session. Investors, analysts and other interested parties are invited to take part. Date: 16 August 2022 Time: 10:00 CET Telephone: DK +45 35445577 UK +44 33 33000804 US +1 631 913 1422 Other international numbers: Access code: 69612122# If you wish to take part in the audio conference, please dial up at least five minutes before the conference begins. It will start on time, and participants will be asked to register name and company name beforehand. The conference will be broadcast live on and published there for future reference. Contact Søren Brøndholt Nielsen, IR +45 33 42 33 59 About DFDS DFDS provid

INVITATION TIL TELE-KONFERENCE OM DFDS' RAPPORT FOR 2. KVT. 20228.8.2022 17:48:27 CEST | pressemeddelelse

INVESTOR NEWS nr. 22 - 8. august 2022 DFDS’ kvartalsrapport for 2. kvt. 2022 forventes offentliggjort 16. august 2022 omkring kl. 07.30. Rapporten præsenteres på en tele-konference af Torben Carlsen, CEO og Karina Deacon, CFO. Efter præsentationen, der foregår på engelsk, vil der være mulighed for at stille spørgsmål. Investorer, analytikere og andre er velkommen til at deltage. Dato: 16. august 2022 Tidspunkt: Kl. 10.00 Telefonnumre: DK +45 35445577 UK +44 33 33000804 US +1 631 913 1422 Øvrige internationale telefonnumre: Adgangskode: 69612122# Deltagere i tele-konferencen bedes ringe mindst fem minutter før starttidspunktet, da konferencen begynder rettidigt, og deltagere forinden skal registreres med navn og firmanavn. Tele-konferencen kan følges live på og vil efterfølgende være tilgængelig på samme sted. Kontakt Søren Brøndholt Nielsen, IR +45 33 42 33 59 Om DFDS DFDS

Avance Gas Holding Ltd: 2022 Annual General Meeting8.8.2022 17:29:53 CEST | Press release

Hamilton, Bermuda 8 August 2022 - Avance Gas Holding Ltd (the "Company") advises that the 2022 Annual General Meeting of the Company will be held on September 30, 2022. The record date for voting at the Annual General Meeting is set to August 19, 2022. The notice, agenda and associated material will be distributed prior to the meeting. For further queries, please contact Executive Chairman: Øystein Kalleklev Tel: 47 23 11 40 00 About Avance Gas: Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carrier (VLGC) and operates a fleet of thirteen modern ships including two dual fuel LPG newbuidlings and has a further four dual fuel LPG newbuildings due for delivery in Q4 2022 and Q1-Q4 2023. For more information about Avance Gas, please visit This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities